Not Tagged
sorrento therapeutics,spdr s&p biotech,ishares biotechnology
['solid tumor', '$ibb', '$xbi', '$srne']
$srne shanghai escugen's trop2 antibody drug conjugate esg-401 shows positive results in first-in-human study for locally advanced/metastatic solid tumors at asco 2023 meeting. more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt